{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:58:52Z","timestamp":1792195132853,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s11523-025-01156-2","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T08:09:00Z","timestamp":1750752540000},"page":"693-705","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Discontinuation of Immune Checkpoint Inhibition in Patients with Advanced Unresectable Melanoma Achieving CR, PR, or SD"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2107-3810","authenticated-orcid":false,"given":"Anna M.","family":"Czarnecka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Teterycz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Ostaszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"B\u0142o\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Zieli\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Galus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Dziura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasza","family":"Kempa-Kami\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Galwas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo\u017cena","family":"Cybulska-Stopa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Mackiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Zi\u0119tek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gra\u017cyna","family":"Kami\u0144ska-Winciorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Kozak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"issue":"3","key":"1156_CR1","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1158\/2326-6066.CIR-15-0210","volume":"4","author":"A Ribas","year":"2016","unstructured":"Ribas A, Shin DS, Zaretsky J, et al. PD-1 blockade expands intratumoral memory T cells. Cancer Immunol Res. 2016;4(3):194\u2013203. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0210.","journal-title":"Cancer Immunol Res"},{"key":"1156_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.698076","volume":"11","author":"Y Jin","year":"2021","unstructured":"Jin Y, Tan A, Feng J, et al. Prognostic impact of memory CD8(+) T cells on immunotherapy in human cancers: a systematic review and meta-analysis. Front Oncol. 2021;11: 698076. https:\/\/doi.org\/10.3389\/fonc.2021.698076.","journal-title":"Front Oncol"},{"issue":"2","key":"1156_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41435-021-00138-4","volume":"22","author":"I Vanmeerbeek","year":"2021","unstructured":"Vanmeerbeek I, Borras DM, Sprooten J, et al. Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy. Genes Immun. 2021;22(2):108\u201319. https:\/\/doi.org\/10.1038\/s41435-021-00138-4.","journal-title":"Genes Immun"},{"issue":"11","key":"1156_CR4","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41571-020-0399-6","volume":"17","author":"C Robert","year":"2020","unstructured":"Robert C, Marabelle A, Herrscher H, et al. Immunotherapy discontinuation-how, and when? Data from melanoma as a paradigm. Nat Rev Clin Oncol. 2020;17(11):707\u201315. https:\/\/doi.org\/10.1038\/s41571-020-0399-6.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"1156_CR5","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s11912-023-01429-x","volume":"25","author":"C Boutros","year":"2023","unstructured":"Boutros C, Belkadi-Sadou D, Marchand A, et al. Cured or not? Long-term outcomes of immunotherapy responders. Focus on melanoma. Curr Oncol Rep. 2023;25(9):989\u201396. https:\/\/doi.org\/10.1007\/s11912-023-01429-x.","journal-title":"Curr Oncol Rep"},{"issue":"9","key":"1156_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3928\/02793695-20090804-01","volume":"47","author":"RH Howland","year":"2009","unstructured":"Howland RH. Medication holidays. J Psychosoc Nurs Ment Health Serv. 2009;47(9):15\u20138. https:\/\/doi.org\/10.3928\/02793695-20090804-01.","journal-title":"J Psychosoc Nurs Ment Health Serv"},{"key":"1156_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001901","author":"TU Marron","year":"2021","unstructured":"Marron TU, Ryan AE, Reddy SM, et al. Considerations for treatment duration in responders to immune check-point inhibitors. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2020-001901.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"1156_CR8","doi-asserted-by":"publisher","first-page":"28,43","DOI":"10.1097\/01.COT.0000754700.05681.e4","volume":"43","author":"D Kumar Das","year":"2021","unstructured":"Kumar Das D. Clinical outcomes of early immunotherapy cessation in metastatic melanoma. Oncology Times. 2021;43(11):28,43-2943. https:\/\/doi.org\/10.1097\/01.COT.0000754700.05681.e4.","journal-title":"Oncology Times."},{"issue":"8","key":"1156_CR9","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1007\/s11136-022-03110-5","volume":"31","author":"E Beaulieu","year":"2022","unstructured":"Beaulieu E, Spanjaart A, Roes A, et al. Health-related quality of life in cancer immunotherapy: a systematic perspective, using causal loop diagrams. Qual Life Res. 2022;31(8):2357\u201366. https:\/\/doi.org\/10.1007\/s11136-022-03110-5.","journal-title":"Qual Life Res"},{"issue":"7","key":"1156_CR10","first-page":"334","volume":"11","author":"SR Ghate","year":"2018","unstructured":"Ghate SR, Li Z, Tang J, et al. Economic burden of adverse events associated with immunotherapy and targeted therapy for metastatic melanoma in the elderly. Am Health Drug Benefits. 2018;11(7):334\u201343.","journal-title":"Am Health Drug Benefits."},{"issue":"11","key":"1156_CR11","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jamadermatol.2023.3179","volume":"159","author":"SB Bateni","year":"2023","unstructured":"Bateni SB, Nguyen P, Eskander A, et al. Changes in health care costs, survival, and time toxicity in the era of immunotherapy and targeted systemic therapy for melanoma. JAMA Dermatol. 2023;159(11):1195\u2013204. https:\/\/doi.org\/10.1001\/jamadermatol.2023.3179.","journal-title":"JAMA Dermatol"},{"issue":"33","key":"1156_CR12","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1200\/jco.21.01436","volume":"39","author":"RA Adams","year":"2021","unstructured":"Adams RA, Fisher DJ, Graham J, et al. Capecitabine versus active monitoring in stable or responding metastatic colorectal cancer after 16 weeks of first-line therapy: results of the randomised FOCUS4-N trial. J Clin Oncol. 2021;39(33):3693\u2013704. https:\/\/doi.org\/10.1200\/jco.21.01436.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1156_CR13","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1158\/1078-0432.Ccr-10-2654","volume":"17","author":"RA Madan","year":"2011","unstructured":"Madan RA, Pal SK, Sartor O, et al. Overcoming chemotherapy resistance in prostate cancer. Clin Cancer Res. 2011;17(12):3892\u2013902. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-10-2654.","journal-title":"Clin Cancer Res"},{"key":"1156_CR14","doi-asserted-by":"publisher","first-page":"1139659","DOI":"10.3389\/fonc.2023.1139659","volume":"13","author":"C Matsuyama","year":"2023","unstructured":"Matsuyama C, Enokida T, Ueda Y, et al. Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study. Front Oncol. 2023;13:1139659. https:\/\/doi.org\/10.3389\/fonc.2023.1139659.","journal-title":"Front Oncol"},{"issue":"3","key":"1156_CR15","doi-asserted-by":"publisher","first-page":"e663","DOI":"10.1016\/j.clgc.2017.12.014","volume":"16","author":"K Mittal","year":"2018","unstructured":"Mittal K, Derosa L, Albiges L, et al. Drug holiday in metastatic renal-cell carcinoma patients treated with vascular endothelial growth factor receptor inhibitors. Clin Genitourinary Cancer. 2018;16(3):e663\u20137. https:\/\/doi.org\/10.1016\/j.clgc.2017.12.014.","journal-title":"Clin Genitourinary Cancer."},{"issue":"1","key":"1156_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s12253-017-0345-9","volume":"25","author":"K Nagyiv\u00e1nyi","year":"2019","unstructured":"Nagyiv\u00e1nyi K, Budai B, K\u00fcronya Z, et al. Outcome of restarted sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective trial and combined case reports from literature. Pathol Oncol Res. 2019;25(1):241\u20137. https:\/\/doi.org\/10.1007\/s12253-017-0345-9.","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"1156_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/2159-8290.Cd-17-0682","volume":"8","author":"A Hong","year":"2018","unstructured":"Hong A, Moriceau G, Sun L, et al. Exploiting drug addiction mechanisms to select against MAPKi-resistant melanoma. Cancer Discov. 2018;8(1):74\u201393. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-0682.","journal-title":"Cancer Discov"},{"issue":"4","key":"1156_CR18","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdz011.","journal-title":"Ann Oncol"},{"key":"1156_CR19","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ejca.2021.08.013","volume":"157","author":"O Hamid","year":"2021","unstructured":"Hamid O, Robert C, Daud A, et al. Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. Eur J Cancer. 2021;157:391\u2013402. https:\/\/doi.org\/10.1016\/j.ejca.2021.08.013.","journal-title":"Eur J Cancer"},{"issue":"17","key":"1156_CR20","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","volume":"36","author":"C Robert","year":"2018","unstructured":"Robert C, Ribas A, Hamid O, et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol. 2018;36(17):1668\u201374. https:\/\/doi.org\/10.1200\/JCO.2017.75.6270.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"1156_CR21","doi-asserted-by":"publisher","first-page":"10013","DOI":"10.1200\/JCO.2020.38.15_suppl.10013","volume":"38","author":"GV Long","year":"2020","unstructured":"Long GV, Schachter J, Arance A, et al. Long-term survival from pembrolizumab (pembro) completion and pembro re-treatment: Phase III KEYNOTE-006 in advanced melanoma. J Clin Oncol. 2020;38(15_suppl):10013. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.10013.","journal-title":"J Clin Oncol"},{"issue":"33","key":"1156_CR22","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1200\/JCO.20.00995","volume":"38","author":"C Robert","year":"2020","unstructured":"Robert C, Long GV, Brady B, et al. Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma. J Clin Oncol. 2020;38(33):3937\u201346. https:\/\/doi.org\/10.1200\/JCO.20.00995.","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"1156_CR23","doi-asserted-by":"publisher","first-page":"9522","DOI":"10.1200\/JCO.2022.40.16_suppl.9522","volume":"40","author":"FS Hodi","year":"2022","unstructured":"Hodi FS, Chiarion-Sileni V, Lewis KD, et al. Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067. J Clin Oncol. 2022;40(16 suppl):9522. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.9522.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1156_CR24","first-page":"1","volume":"15","author":"P Rutkowski","year":"2019","unstructured":"Rutkowski P, Wysocki PJ, Nasierowska-Guttmejer A, et al. Cutaneous melanomas-guidelines for diagnostic and therapeutic management. Oncol Clin Pract. 2019;15(1):1\u201319.","journal-title":"Oncol Clin Pract."},{"issue":"6","key":"1156_CR25","first-page":"241","volume":"13","author":"P Rutkowski","year":"2017","unstructured":"Rutkowski P, Wysocki PJ, Nasierowska-Guttmejer A, et al. Cutaneous melanomas-guidelines for diagnostic and therapeutic management. Oncol Clin Pract. 2017;13(6):241\u201358.","journal-title":"Oncol Clin Pract."},{"issue":"6","key":"1156_CR26","doi-asserted-by":"publisher","first-page":"357","DOI":"10.5603\/OCP.2021.0042","volume":"18","author":"P Rutkowski","year":"2022","unstructured":"Rutkowski P, Wysocki PJ, Kozak K, et al. Expert recommendations on diagnostic-therapeutic management of melanoma patients. Oncol Clin Pract. 2022;18(6):357\u201392.","journal-title":"Oncol Clin Pract."},{"issue":"3","key":"1156_CR27","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/cmr.0000000000000885","volume":"33","author":"B Cybulska-Stopa","year":"2023","unstructured":"Cybulska-Stopa B, Piejko K, Ostaszewski K, et al. Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment. Melanoma Res. 2023;33(3):208\u201317. https:\/\/doi.org\/10.1097\/cmr.0000000000000885.","journal-title":"Melanoma Res"},{"issue":"16_suppl","key":"1156_CR28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e21552","volume":"41","author":"K Kozak","year":"2023","unstructured":"Kozak K, Teterycz P, Galus \u0141, et al. Real-world outcomes in advanced melanoma patients treated with first-line nivolumab plus ipilimumab. J Clin Oncol. 2023;41(16_suppl): e21552. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e21552.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1156_CR29","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s11523-019-00688-8","volume":"14","author":"AM Czarnecka","year":"2019","unstructured":"Czarnecka AM, Teterycz P, Mariuk-Jarema A, et al. Treatment sequencing and clinical outcomes in BRAF-positive and BRAF-negative unresectable and metastatic melanoma patients treated with new systemic therapies in routine practice. Target Oncol. 2019;14(6):729\u201342. https:\/\/doi.org\/10.1007\/s11523-019-00688-8.","journal-title":"Target Oncol"},{"issue":"7","key":"1156_CR30","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1093\/annonc\/mdz110","volume":"30","author":"YJL Jansen","year":"2019","unstructured":"Jansen YJL, Rozeman EA, Mason R, et al. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Ann Oncol. 2019;30(7):1154\u201361. https:\/\/doi.org\/10.1093\/annonc\/mdz110.","journal-title":"Ann Oncol"},{"issue":"2","key":"1156_CR31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"1156_CR32","unstructured":"Rutkowski P, Wysocki PJ, Kozak K, et al. Post\u0119powanie diagnostyczno-terapeutyczne u chorych na czerniaki \u2014 zalecenia ekspert\u00f3w. Onkol Prakt Klin Edu. 2021:ahead of print."},{"issue":"4","key":"1156_CR33","first-page":"225","volume":"6","author":"P Rutkowski","year":"2020","unstructured":"Rutkowski P, Wysocki PJ, Nasierowska-Guttmejer A, et al. Czerniaki sk\u00f3ry - wytyczne post\u0119powania diagnostyczno-terapeutycznego. Onkol Prakt Klin Edu. 2020;6(4):225\u201345.","journal-title":"Onkol Prakt Klin Edu."},{"issue":"282","key":"1156_CR34","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457\u201381. https:\/\/doi.org\/10.1080\/01621459.1958.10501452.","journal-title":"J Am Stat Assoc"},{"issue":"6","key":"1156_CR35","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1089\/sur.2020.425","volume":"22","author":"AC Cioci","year":"2021","unstructured":"Cioci AC, Cioci AL, Mantero AMA, et al. Advanced statistics: multiple logistic regression, Cox proportional hazards, and propensity scores. Surg Infect (Larchmt). 2021;22(6):604\u201310. https:\/\/doi.org\/10.1089\/sur.2020.425.","journal-title":"Surg Infect (Larchmt)"},{"issue":"12","key":"1156_CR36","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","volume":"30","author":"O Michielin","year":"2019","unstructured":"Michielin O, van Akkooi ACJ, Ascierto PA, et al. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(12):1884\u2013901. https:\/\/doi.org\/10.1093\/annonc\/mdz411.","journal-title":"Ann Oncol"},{"issue":"35","key":"1156_CR37","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1200\/jco.19.00345","volume":"37","author":"MM Regan","year":"2019","unstructured":"Regan MM, Werner L, Rao S, et al. Treatment-free survival: a novel outcome measure of the effects of immune check-point inhibition-a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2019;37(35):3350\u20138. https:\/\/doi.org\/10.1200\/jco.19.00345.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1156_CR38","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.19607","volume":"6","author":"M Gupta","year":"2023","unstructured":"Gupta M, Stukalin I, Meyers D, et al. Treatment-free survival after nivolumab vs pembrolizumab vs nivolumab-ipilimumab for advanced melanoma. JAMA Netw Open. 2023;6(6): e2319607. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.19607.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"1156_CR39","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239\u201351. https:\/\/doi.org\/10.1016\/S1470-2045(19)30388-2.","journal-title":"Lancet Oncol"},{"issue":"24","key":"1156_CR40","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1200\/JCO.22.01599","volume":"41","author":"C Robert","year":"2023","unstructured":"Robert C, Carlino MS, McNeil C, et al. Seven-year follow-up of the phase III KEYNOTE-006 study: pembrolizumab versus ipilimumab in advanced melanoma. J Clin Oncol. 2023;41(24):3998\u20134003. https:\/\/doi.org\/10.1200\/JCO.22.01599.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1156_CR41","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.annonc.2024.08.2330","volume":"35","author":"GV Long","year":"2024","unstructured":"Long GV, Carlino MS, McNeil C, et al. Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Ann Oncol. 2024;35(12):1191\u20139. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2330.","journal-title":"Ann Oncol"},{"issue":"1","key":"1156_CR42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"D Wolchok Jedd","year":"2025","unstructured":"Wolchok Jedd D, Chiarion-Sileni V, Rutkowski P, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2025;392(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa2407417.","journal-title":"N Engl J Med"},{"key":"1156_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001781","author":"R Pokorny","year":"2021","unstructured":"Pokorny R, McPherson JP, Haaland B, et al. Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2020-001781.","journal-title":"J Immunother Cancer"},{"key":"1156_CR44","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejca.2021.02.037","volume":"149","author":"F Dimitriou","year":"2021","unstructured":"Dimitriou F, Zaremba A, Allayous C, et al. Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. Eur J Cancer. 2021;149:37\u201348. https:\/\/doi.org\/10.1016\/j.ejca.2021.02.037.","journal-title":"Eur J Cancer"},{"key":"1156_CR45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejca.2023.03.020","volume":"187","author":"M Rubatto","year":"2023","unstructured":"Rubatto M, Fava P, Stanganelli I, et al. Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup. Eur J Cancer. 2023;187:25\u201335. https:\/\/doi.org\/10.1016\/j.ejca.2023.03.020.","journal-title":"Eur J Cancer"},{"issue":"7","key":"1156_CR46","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s11912-022-01264-6","volume":"24","author":"Y Jansen","year":"2022","unstructured":"Jansen Y, van der Veldt AAM, Awada G, et al. Anti-PD-1: when to stop treatment. Curr Oncol Rep. 2022;24(7):905\u201315. https:\/\/doi.org\/10.1007\/s11912-022-01264-6.","journal-title":"Curr Oncol Rep"},{"key":"1156_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009440","author":"L Paolini","year":"2024","unstructured":"Paolini L, Tran T, Corgnac S, et al. Differential predictive value of resident memory CD8(+)T cell subpopulations in patients with non-small-cell lung cancer treated by immunotherapy. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2024-009440.","journal-title":"J Immunother Cancer"},{"issue":"13","key":"1156_CR48","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1158\/1078-0432.CCR-17-2257","volume":"24","author":"J Edwards","year":"2018","unstructured":"Edwards J, Wilmott JS, Madore J, et al. CD103(+) tumor-resident CD8(+) T cells are associated with improved survival in immunotherapy-naive melanoma patients and expand significantly during anti-PD-1 treatment. Clin Cancer Res. 2018;24(13):3036\u201345. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2257.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1156_CR49","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/ijc.33800","volume":"150","author":"MCT van Zeijl","year":"2022","unstructured":"van Zeijl MCT, van den Eertwegh AJM, Wouters M, et al. Discontinuation of anti-PD-1 monotherapy in advanced melanoma-Outcomes of daily clinical practice. Int J Cancer. 2022;150(2):317\u201326. https:\/\/doi.org\/10.1002\/ijc.33800.","journal-title":"Int J Cancer"},{"issue":"12","key":"1156_CR50","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1001\/jamadermatol.2022.4556","volume":"158","author":"Z Cartun","year":"2022","unstructured":"Cartun Z, Kunz WG, Heinzerling L, et al. Cost-effectiveness of response-adapted de-escalation of immunotherapy in advanced melanoma. JAMA Dermatol. 2022;158(12):1387\u201393. https:\/\/doi.org\/10.1001\/jamadermatol.2022.4556.","journal-title":"JAMA Dermatol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01156-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01156-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01156-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T22:29:38Z","timestamp":1757197778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01156-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1156"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01156-2","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"assertion":[{"value":"15 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"PR has served on an advisory board in a personal capacity for Blueprint Medicines; has served as an invited speaker and on an advisory board in a personal capacity and received honoraria for lectures from BMS, MSD, and Pierre Fabre; has served as an invited speaker and on an advisory board in a personal capacity for Merck and Sanofi; has served as an invited speaker in a personal capacity for Novartis; has received funding and a research grant to his institution from, and has a financial interest in, BMS; has received a research grant to his institution, has a financial interest in, and has received a research grant for ISS from Pfizer; serves as an officer for the American Society of Oncology; and is a member of the board of directors of the Polish Society of Surgical Oncology. AMC, \u0141G, RD, NKK, KG, BCS, JM, MZi\u0119t, GKW, KK have delivered lectures for and received fees, honoraria, and travel accommodations from BMS, MSF, and Pierre Fabre. PT, KO, PB, and MZiel have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Patients were treated under National Treatment Reimbursement Program B.59 as per the Announcement of the Minister of Health. All patients signed informed consent for the treatment. Data analysis was approved by the local ethical committee in Maria Sklodowska-Curie National Research Institute of Oncology (approval no. KB\/430-74\/20 from October 23, 2020).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients signed informed consent for the treatment, data processing, utilization for scientific research purposes, and publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All patients signed informed consent for the treatment, data processing, utilization for scientific research purposes, and publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The code created and used during the current study is available from the corresponding author on reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization: AMC, PT, KO, and PR. Methodology: AMC, PT, and PR. Software: AMC and PT. Data curation: AMC, KO, and PB. Investigation: all authors. Validation: AMC, PT, KO, and PB. Formal analysis: PT, AMC, and PR. Supervision: AMC and PR. Funding acquisition: PR. Visualization: PT. Project administration: AMC. Resources: AMC and PR. Writing \u2013 original draft: AMC, PT, PB, and PR. Writing \u2013 review and editing: all authors.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}